Furthermore, comparison of individual post-treatment biomarkers revealed that after adjuvant treatment the t-PA antigen had the highest AUC value (AUC = 0.757, p = 0.0001) indicating that a t-PA antigen concentration of 3.13 ng/mL may reliably predict post-treatment outcomes in patients’ breast cancer with a specificity of 59.2% and a sensitivity of 90.9%. This evidence concerns the gene PLAT and breast cancer.